We are grateful to Dr. MacLeod and his colleagues for raising this important suggestion. As they commented, in several cases it is not possible to rule out accidental inclusion of syngeneic subclones in the analysis due to cell line cross-contamination. Therefore, such cell line cross-contamination
✦ LIBER ✦
Reply to the letter by Y. Ni et al. regarding ‘‘Expression of OATP1B3’’
✍ Scribed by Etsuro Hatano; Masato Narita; Shigeki Arizono; Hiroyoshi Isoda; Shinji Uemoto
- Publisher
- Springer Japan
- Year
- 2009
- Tongue
- English
- Weight
- 97 KB
- Volume
- 45
- Category
- Article
- ISSN
- 0944-1174
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Reply to the letter by MacLeod et al.
✍
Hisashi Kubota; Takafumi Nishizaki; Kohsuke Sasaki
📂
Article
📅
2001
🏛
John Wiley and Sons
🌐
English
⚖ 28 KB
Reply to the letter by Kling et al.
✍
Manfred Wehnert; Winnie Schröder; Falko H. Herrmann
📂
Article
📅
1992
🏛
Springer
🌐
English
⚖ 125 KB
Reply to the letter by S. Montagnese et
✍
Ulrich Thalheimer; Andrew K. Burroughs
📂
Article
📅
2009
🏛
Springer Japan
🌐
English
⚖ 95 KB
Reply to the letter by O. Riggio et al.
✍
Ulrich Thalheimer; Andrew K. Burroughs
📂
Article
📅
2010
🏛
Springer Japan
🌐
English
⚖ 87 KB
Reply to the letter by J. Molina-Infante
✍
Yasuhiko Abe; Katsunori Iijima; Tomoyuki Koike; Tooru Shimosegawa
📂
Article
📅
2011
🏛
Springer Japan
🌐
English
⚖ 107 KB
In reply to the letter by Gevaert et al.
✍
Jozien Helleman; Maurice P.H.M. Jansen; Maria E.L. van der Burg; Els M.J.J. Bern
📂
Article
📅
2006
🏛
John Wiley and Sons
🌐
French
⚖ 40 KB
raised an important issue about the implementation in clinical practice of the 9-gene set for platinum resistance of ovarian cancer patients. They also stated that nonplatinum containing regimens are suboptimal in the treatment of ovarian cancer. In our study 1 we have included specimens of 96 prim